Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A Combination Trial of Copaxone plus Estriol in Relapsing Remitting Multiple Sclerosis
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update.
Extraocular Source of Oligodendrocytes Contribute to Retinal Myelination and Optokinetic Responses in Zebrafish.
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.
Techniques and technologies for the bioanalysis of Sativex(®), metabolites and related compounds.
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
Episode 28 with Dr. Brenda Banwell on pediatric MS
Sleep and Cognitive Function in Multiple Sclerosis.
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a)
Mast cell inflammasome activity in the meninges regulates EAE disease severity.
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate.
Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin.
Interferon-beta-1b protects against multiple sclerosis-induced endothelial cells apoptosis.
Full Prescribing Information, Copaxone (glatiramer acetate)
Characterization and quantitation of aggregates and particles in interferon-β products: Potential links between product quality attributes and immunogenicity.
Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients.
Tumefactive multiple sclerosis presenting with tonic-clonic seizure.
Differing trends in the incidence of vascular comorbidity in MS and the general population.
A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis.
Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators.
[The overall assessment of the quality of the physical health of patients with multiple sclerosis after the application of physical therapy. Part 1].
Prevalence of Multiple Sclerosis in the Republic of Moldova.

Pages